At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 199 enrolled
Drug / intervention
DCV/ASV/BMS-791325drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
In Brief
A Phase 3 clinical trial evaluating DCV/ASV/BMS-791325 for Hepatitis C Virus. Completed, enrolled 199 participants across 20 sites in 3 countries.
Detailed Summary
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus
CountriesRussia, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJun 2014
Primary CompletionJun 2015
Study CompletionSep 2015
TodayJul 2026
First PostedJun 23, 2014
Enrollment StartJun 26, 2014
Primary CompletionJun 12, 2015
Study CompletionSep 9, 2015
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 12.0 years ago
Interventions
DCV/ASV/BMS-791325drug